ES2785053T3 - Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma - Google Patents
Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma Download PDFInfo
- Publication number
- ES2785053T3 ES2785053T3 ES18180366T ES18180366T ES2785053T3 ES 2785053 T3 ES2785053 T3 ES 2785053T3 ES 18180366 T ES18180366 T ES 18180366T ES 18180366 T ES18180366 T ES 18180366T ES 2785053 T3 ES2785053 T3 ES 2785053T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- pi3k
- bid
- gamma
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882473P | 2013-09-25 | 2013-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2785053T3 true ES2785053T3 (es) | 2020-10-05 |
Family
ID=51795739
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14789651.8T Active ES2687593T3 (es) | 2013-09-25 | 2014-09-25 | Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma |
| ES18180366T Active ES2785053T3 (es) | 2013-09-25 | 2014-09-25 | Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14789651.8T Active ES2687593T3 (es) | 2013-09-25 | 2014-09-25 | Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10301304B2 (enExample) |
| EP (2) | EP3049415B1 (enExample) |
| JP (1) | JP6340416B2 (enExample) |
| KR (1) | KR20160058950A (enExample) |
| CN (1) | CN105722838B (enExample) |
| AU (1) | AU2014324873B2 (enExample) |
| BR (1) | BR112016006388A2 (enExample) |
| CA (1) | CA2925601C (enExample) |
| CL (1) | CL2016000695A1 (enExample) |
| ES (2) | ES2687593T3 (enExample) |
| IL (1) | IL244742A0 (enExample) |
| MX (1) | MX2016003823A (enExample) |
| RU (2) | RU2675814C2 (enExample) |
| SG (2) | SG10201802061TA (enExample) |
| UA (1) | UA117032C2 (enExample) |
| WO (1) | WO2015048318A1 (enExample) |
| ZA (1) | ZA201702252B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| HK1254954A1 (zh) | 2015-06-29 | 2019-08-02 | Biomed Valley Discoveries, Inc. | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 |
| AU2016322552B2 (en) | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| US10858355B2 (en) | 2016-03-10 | 2020-12-08 | Astrazeneca Ab | Inhibitors of phosphatidylinositol 3-kinase gamma |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2020210379A1 (en) | 2019-04-10 | 2020-10-15 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Phosphatidylinositol 3-kinase inhibitors |
| EP3980010A4 (en) | 2019-06-04 | 2023-06-07 | Arcus Biosciences, Inc. | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
| WO2025228895A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228892A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2009001152A1 (es) * | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| KR101758046B1 (ko) * | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
-
2014
- 2014-09-25 SG SG10201802061TA patent/SG10201802061TA/en unknown
- 2014-09-25 ES ES14789651.8T patent/ES2687593T3/es active Active
- 2014-09-25 SG SG11201602265PA patent/SG11201602265PA/en unknown
- 2014-09-25 JP JP2016516904A patent/JP6340416B2/ja not_active Expired - Fee Related
- 2014-09-25 ES ES18180366T patent/ES2785053T3/es active Active
- 2014-09-25 KR KR1020167010907A patent/KR20160058950A/ko not_active Withdrawn
- 2014-09-25 MX MX2016003823A patent/MX2016003823A/es unknown
- 2014-09-25 WO PCT/US2014/057499 patent/WO2015048318A1/en not_active Ceased
- 2014-09-25 US US15/024,698 patent/US10301304B2/en active Active
- 2014-09-25 UA UAA201604461A patent/UA117032C2/uk unknown
- 2014-09-25 CA CA2925601A patent/CA2925601C/en active Active
- 2014-09-25 EP EP14789651.8A patent/EP3049415B1/en not_active Not-in-force
- 2014-09-25 RU RU2016115726A patent/RU2675814C2/ru not_active IP Right Cessation
- 2014-09-25 CN CN201480060785.XA patent/CN105722838B/zh not_active Expired - Fee Related
- 2014-09-25 EP EP18180366.9A patent/EP3412668B1/en active Active
- 2014-09-25 BR BR112016006388A patent/BR112016006388A2/pt not_active Application Discontinuation
- 2014-09-25 RU RU2018142605A patent/RU2018142605A/ru unknown
- 2014-09-25 AU AU2014324873A patent/AU2014324873B2/en not_active Ceased
-
2016
- 2016-03-23 IL IL244742A patent/IL244742A0/en unknown
- 2016-03-24 CL CL2016000695A patent/CL2016000695A1/es unknown
-
2017
- 2017-03-30 ZA ZA2017/02252A patent/ZA201702252B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016115726A (ru) | 2017-10-30 |
| CN105722838B (zh) | 2017-10-24 |
| SG11201602265PA (en) | 2016-04-28 |
| CN105722838A (zh) | 2016-06-29 |
| EP3049415A1 (en) | 2016-08-03 |
| EP3412668B1 (en) | 2020-02-05 |
| AU2014324873A1 (en) | 2016-04-21 |
| ES2687593T3 (es) | 2018-10-26 |
| CA2925601A1 (en) | 2015-04-02 |
| RU2018142605A (ru) | 2019-02-04 |
| ZA201702252B (en) | 2019-06-26 |
| RU2675814C2 (ru) | 2018-12-25 |
| JP2016531861A (ja) | 2016-10-13 |
| JP6340416B2 (ja) | 2018-06-06 |
| EP3412668A2 (en) | 2018-12-12 |
| CL2016000695A1 (es) | 2017-06-09 |
| EP3049415B1 (en) | 2018-07-04 |
| US10301304B2 (en) | 2019-05-28 |
| AU2014324873B2 (en) | 2018-11-08 |
| UA117032C2 (uk) | 2018-06-11 |
| HK1223620A1 (zh) | 2017-08-04 |
| CA2925601C (en) | 2022-11-01 |
| KR20160058950A (ko) | 2016-05-25 |
| IL244742A0 (en) | 2016-04-21 |
| SG10201802061TA (en) | 2018-05-30 |
| BR112016006388A2 (pt) | 2017-08-01 |
| EP3412668A3 (en) | 2018-12-19 |
| MX2016003823A (es) | 2016-08-01 |
| WO2015048318A1 (en) | 2015-04-02 |
| US20160214980A1 (en) | 2016-07-28 |
| RU2016115726A3 (enExample) | 2018-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2785053T3 (es) | Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma | |
| ES2842399T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| ES2773046T3 (es) | Cianopirrolidinas como inhibidores de DUB para el tratamiento del cáncer | |
| RU2537945C2 (ru) | Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб | |
| ES2857549T3 (es) | Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos | |
| ES2925211T3 (es) | 2-oxo-imidazopiridinas como inhibidores de BTK reversibles y usos de las mismas | |
| ES2974208T3 (es) | Inhibidores de PDE4 que contienen boro | |
| JP2018514518A (ja) | インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ | |
| BR112016007467B1 (pt) | Compostos heterocíclicos e usos dos mesmos | |
| KR20120034607A (ko) | 이미다조〔2,1-ｂ〕〔1,3,4〕티아디아졸 유도체 | |
| ES2968804T3 (es) | Derivado de azaarilo, método de preparación del mismo y uso farmacéutico del mismo | |
| ES2731802T3 (es) | Derivados de naftiridinodiona como supresores de mutaciones sin sentido | |
| US10196383B2 (en) | Substituted quinazoline compounds and preparation and uses thereof | |
| ES2709003T3 (es) | Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico | |
| ES2958528T3 (es) | Macrociclos sustituidos útiles como inhibidores de quinasas | |
| KR102288246B1 (ko) | 라파마이신 신호전달 경로 저해제의 기계적 표적 및 이의 치료학적 적용 | |
| KR20160067946A (ko) | 구조적으로 제한된 PI3K 및 mTOR 억제제 | |
| Li et al. | Discovery of 2 (1 H)-Quinoxalinone Derivatives as Potent and Selective MAT2A Inhibitors for the Treatment of MTAP-Deficient Cancers | |
| ES2609459T3 (es) | Compuestos heterocíclicos condensados y su uso | |
| TWI546304B (zh) | Protein tyrosine kinase inhibitors and their use | |
| AU2018447240B2 (en) | Indazole kinase inhibitor and use thereof | |
| Hamajima et al. | Optimization of 5, 6, 7, 8-tetrahydropyrido [4, 3-d] pyrimidines to generate a highly selective PI3Kδ inhibitor | |
| HK1227408B (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| HK1223620B (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| CN109942562A (zh) | 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用 |